[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650818":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":61,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Overall RCC population",null,"Patients diagnosed with local RCC or high-risk locally advanced RCC.",[13],"Other: Cohort 1",{"label":15,"type":10,"description":15,"interventionNames":16},"Non clear RCC population",[17],"Other: Cohort 2",{"label":19,"type":10,"description":20,"interventionNames":21},"Clear RCC population stratified by eligibility based on the Keynote-564 study criteria","Keynote-564 study criteria: pT2 grade 4, pT3-T4 with any N and any grade, any T with N1, all M0",[22],"Other: Cohort 3",[24,28,31],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Cohort 1","Overall RCC Population",[9],{"type":6,"name":29,"description":15,"armGroupLabels":30,"otherNames":10},"Cohort 2",[15],{"type":6,"name":32,"description":19,"armGroupLabels":33,"otherNames":10},"Cohort 3",[19],[35],{"name":36,"affiliation":5,"role":37},"Jean-Christophe BERNHARD, Pr","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":10,"email":42},"CONTACT","0033540451179","jean-christophe.bernhard@chu-bordeaux.fr",{"name":44,"role":40,"phone":10,"phoneExt":10,"email":10},"Gaelle MARGUE, Dr",[46],{"facility":47,"status":48,"city":49,"state":10,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"CHU Bordeaux","RECRUITING","Bordeaux","33000","France","FR",{"type":54,"coordinates":55},"Point",[56,57],-0.58046,44.84124,{"lat":57,"lon":56},[60],{"name":36,"role":40,"phone":41,"phoneExt":10,"email":42},{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100650818","identification-and-description-of-patients-with-high-risk-non-metastatic-rcc-100650818",false,"NCT07753343","Identification and Description of Patients With High-risk Non Metastatic RCC","Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)","HIROES","Inclusion Criteria:\n\n* Adult patients diagnosed with local RCC or high-risk locally advanced RCC,\n* Included in UroCCR register between 1st january 2014 and 31st december 2023,\n* Consenting to participate in UroCCR and UroCCR-Chain registers.\n\nExclusion Criteria:\n\n* Patients with metastatic disease at inclusion,\n* Patients not linked between UroCCR and SNDS datasources,\n* Patients with hereditary RCC.","ALL","18 Years",{"count":74,"type":75},6109,"ESTIMATED","OBSERVATIONAL","Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions",[79],"Renal Cell Carcinoma",[81,82,83,84],"renal cell carcinoma (RCC) high-risk RCC","real life","UroCCR","UroCCR-Chain","2026-08-05",{"date":87,"type":88},"2026-08-07","ACTUAL",{"date":90,"type":88},"2026-04-17",{"date":92,"type":75},"2028-04-17",{"name":5,"class":6},1]